TNXP Stock Forecast: Tonix Pharmaceuticals Holding Corp. Price Predictions for 2026-2027
The median 12-month analyst price target for Tonix Pharmaceuticals Holding Corp. is $22. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 22 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Tonix Pharmaceuticals Holding Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (65): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (6): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
TNXP stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on TNXP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 Oct 2026 | Canaccord Genuity | Initiates | Buy | $18 |
| 25 June 2026 | Raymond James | Initiates | Strong Buy | $26 |
| 4 May 2026 | TD Cowen | Initiates | Buy | — |
| 20 Mar 2025 | Noble Capital Markets | Reiterates | Outperform | — |
| 22 July 2024 | Alliance Global Partners | Maintains | Buy | — |
| 28 Feb 2024 | Dawson James | Initiates | Buy | — |
| 1 Aug 2023 | Alliance Global Partners | Maintains | Buy | — |
| 2 June 2023 | Alliance Global Partners | Maintains | Buy | — |
| 12 Jan 2023 | Alliance Global Partners | Reiterates | Buy | $6.50 |
| 18 Apr 2022 | Noble Capital Markets | Initiates | Outperform | $0.60 |
| 31 Aug 2021 | Alliance Global Partners | Maintains | Buy | — |
| 11 Aug 2021 | Alliance Global Partners | Maintains | Buy | — |
| 25 Feb 2021 | Alliance Global Partners | Maintains | Buy | — |
| 18 Nov 2019 | B. Riley FBR | Downgrade | Neutral | — |
| 18 Nov 2019 | Cantor Fitzgerald | Downgrade | Hold | — |
| 18 Nov 2019 | Janney Capital | Initiates | Buy | — |
| 18 Nov 2019 | Oppenheimer | Maintains | Outperform | — |
| 18 Nov 2019 | Roth Capital | Upgrade | Buy | — |
| 18 Apr 2019 | Roth Capital | Upgrade | Buy | — |
| 27 July 2018 | B. Riley FBR | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TNXP.
This page is one stock. Monday covers all of them.
TNXP appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
TNXP vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Tonix Pharmaceuticals Holding Corp. returned −84.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
TNXP analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 1.1×
- Price / book
- 0.2×
- EV / EBITDA
- —
Cheaper than 64% of US stocks
Cheaper than 93% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 94.8%
- Operating margin
- —
- Net margin
- —
Higher than 98% of US stocks
- Return on equity
- −84.1%
- Return on assets
- −47.4%
- Dividend yield
- —
Higher than 15% of US stocks
Higher than 8% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Tonix Pharmaceuticals Holding Corp. has a market value of $46.2M.
Revenue in the twelve months to 30 June 2026: $29.1M. The latest quarter grew 577.9% year on year.
Net income over the same four quarters: −$159.7M, a −548.6% net margin.
Diluted earnings per share, trailing twelve months: −$12.94.
Free cash flow in the twelve months to 30 June 2026: −$156.1M.
Tonix Pharmaceuticals Holding Corp. spent $7.8M on share buybacks in the twelve months to 30 June 2026.
Tonix Pharmaceuticals Holding Corp. employs 142 people — $205K of revenue per employee.
Data provided by Twelve Data
TNXP and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at TNXP’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Tonix Pharmaceuticals Holding Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about TNXP
What is the TNXP stock price forecast for 2026-2027?
The median 12-month analyst price target for Tonix Pharmaceuticals Holding Corp. is $22, with estimates ranging from $14 to $56. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is TNXP stock a buy right now?
Of the 4 analysts covering Tonix Pharmaceuticals Holding Corp., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tonix Pharmaceuticals Holding Corp. 22 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank TNXP?
As at 21 Nov 2026, Tonix Pharmaceuticals Holding Corp. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (65 of 100).
Will TNXP stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts is $22, and Ticker Nerd's factor model ranks Tonix Pharmaceuticals Holding Corp. 22 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the TNXP stock forecast for 2030?
No analyst covering Tonix Pharmaceuticals Holding Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNXP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $56 over the next 12 months.
How has TNXP stock performed over the past year?
Tonix Pharmaceuticals Holding Corp. returned -84.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Tonix Pharmaceuticals Holding Corp. do?
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders, immunology and immuno-oncology, infectious diseases, and rare diseases. Tonix Pharmaceuticals Holding Corp. markets approved and late-stage products for conditions with significant unmet medical need, including TONMYA for fibromyalgia and additional medicines used in migraine care.
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders, immunology and immuno-oncology, infectious diseases, and rare diseases. Tonix Pharmaceuticals Holding Corp. markets approved and late-stage products for conditions with significant unmet medical need, including TONMYA for fibromyalgia and additional medicines used in migraine care. The company’s pipeline includes programs aimed at neurological, infectious, and immune-related diseases, reflecting a broad research and development platform built around small molecules and biologics. Tonix Pharmaceuticals Holding Corp. serves the U.S. healthcare market through a combination of commercial products, clinical development programs, and disease-focused collaborations. Its role in the financial market is defined by its position as a commercial-stage biotechnology business with a diversified therapeutic portfolio and ongoing pipeline activity.
CEO Dr. Seth Lederman M.D. · 142 employees · United States · https://www.tonixpharma.com